
Launching Cutting-Edge CAR-T Oncology Technology in Saudi Arabia
We provided a comprehensive market access pathway
The Concept
Our company successfully supported the market entry and implementation of a novel CAR-T (Chimeric Antigen Receptor T-cell) therapy in the Kingdom of Saudi Arabia — a milestone in advanced oncology treatment for the region. This project highlights our end-to-end capabilities in enabling medtech companies to navigate complex healthcare ecosystems in the Middle East.
Industry
Oncology
Challenge
A leading biopharmaceutical innovator sought to introduce its CAR-T therapy to a key oncology center in Saudi Arabia. The goal was to achieve clinical access, ensure compliant cell transportation logistics, and secure regulatory approval from the Ministry of Health (MOH)
Result
Hospital Access: We facilitated clinical engagement and onboarding of a tier-one Saudi hospital with CAR-T capabilities, aligning all technical and administrative requirements with the treatment protocol. Cell Transport Logistics: Our team managed time-critical international logistics for autologous cell collection and return, ensuring full chain-of-custody compliance and alignment with hospital scheduling and temperature-control protocols. MOH Regulatory Registration: We coordinated with the client’s regulatory team and local partners to expedite registration and approval of the CAR-T therapy with the Saudi Ministry of Health, addressing unique documentation and clinical trial linkage requirements.
More
Projects
Tripling Medtech Partner Sales in Qatar — From $17M to $55M in 4 Years
Our company partnered with a leading medtech distributor in Qatar to drive the sales growth of an international medical technology manufacturer — increasing annual revenue from $17 million to $55 million in just four years.
Rapid Deployment of 20 Million Vaccine Doses Across Sub-Saharan Africa
We partnered with a global vaccine manufacturer to deliver 20 million doses across multiple sub-Saharan African countries in just six months